Literature DB >> 21965737

Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration.

Bruce C Casto1, Michael A Pereira.   

Abstract

BACKGROUND: Concurrent and sequential administration of combinations of budesonide, bexarotene, suberoylanilide hydroxamic acid (SAHA) and atorvastatin were evaluated in A/J mice for prevention of lung tumors initiated by 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol, NNK).
MATERIALS AND METHODS: Individual drugs and their combinations were administered for 26 weeks after NNK initiation. For sequential administration, budesonide was given for 21 weeks followed by a second drug.
RESULTS: Alone, budesonide, bexarotene, and SAHA caused a significant decrease in total and large tumors at 21 and 26 weeks. Concurrent treatment with budesonide and bexarotene or SAHA caused a significantly greater decrease in total tumors and large tumors than either drug administered alone. Sequential administration of all combinations (except budesonide/atorvastatin) gave a significant reduction in total and large tumors. Budesonide followed by SAHA and SAHA with atorvastatin yielded a greater reduction in large tumors.
CONCLUSION: Combinations of drugs demonstrated a greater efficacy in preventing mouse lung tumors than did the individual agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21965737

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.

Authors:  Silvio De Flora; Gancho Ganchev; Marietta Iltcheva; Sebastiano La Maestra; Rosanna T Micale; Vernon E Steele; Roumen Balansky
Journal:  Trends Pharmacol Sci       Date:  2015-12-23       Impact factor: 14.819

2.  The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.

Authors:  Kim Tran; Renee Risingsong; Darlene B Royce; Charlotte R Williams; Michael B Sporn; Patricia A Pioli; Lalji K Gediya; Vincent C Njar; Karen T Liby
Journal:  Carcinogenesis       Date:  2012-10-06       Impact factor: 4.944

3.  Relationships between pulmonary micro-RNA and proteome profiles, systemic cytogenetic damage and lung tumors in cigarette smoke-exposed mice treated with chemopreventive agents.

Authors:  Alberto Izzotti; Roumen Balansky; Francesco D'Agostini; Mariagrazia Longobardi; Cristina Cartiglia; Sebastiano La Maestra; Rosanna T Micale; Anna Camoirano; Gancho Ganchev; Marietta Iltcheva; Vernon E Steele; Silvio De Flora
Journal:  Carcinogenesis       Date:  2013-05-24       Impact factor: 4.944

4.  Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

Authors:  Stefan Prekovic; Karianne Schuurman; Isabel Mayayo-Peralta; Anna G Manjón; Mark Buijs; Selçuk Yavuz; Max D Wellenstein; Alejandro Barrera; Kim Monkhorst; Anne Huber; Ben Morris; Cor Lieftink; Theofilos Chalkiadakis; Ferhat Alkan; Joana Silva; Balázs Győrffy; Liesbeth Hoekman; Bram van den Broek; Hans Teunissen; Donna O Debets; Tesa Severson; Jos Jonkers; Timothy Reddy; Karin E de Visser; William Faller; Roderick Beijersbergen; Maarten Altelaar; Elzo de Wit; Rene Medema; Wilbert Zwart
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.